Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Treatment escalation and rise in HbA1c following successful initial metformin therapy.

Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB.

Diabetes Care. 2006 Mar;29(3):504-9.

PMID:
16505496
2.

Contemporary analysis of secondary failure of successful sulfonylurea therapy.

Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB.

Endocr Pract. 2007 Jan-Feb;13(1):37-44.

PMID:
17360299
3.
4.

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.

Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR.

Diabetes Care. 2005 May;28(5):995-1000.

PMID:
15855556
5.
6.

Secondary failure of metformin monotherapy in clinical practice.

Brown JB, Conner C, Nichols GA.

Diabetes Care. 2010 Mar;33(3):501-6. doi: 10.2337/dc09-1749. Epub 2009 Dec 29.

7.
10.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

Diabetes Care. 2006 Dec;29(12):2638-43.

PMID:
17130197
13.

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

Pharmacotherapy. 2005 Jun;25(6):810-6.

PMID:
15927899
14.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
15.

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M.

Curr Med Res Opin. 2008 Feb;24(2):537-50. doi: 10.1185/030079908X260925 .

PMID:
18194595
16.
17.

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.

Diabetes Obes Metab. 2009 Jan;11(1):27-32. Epub 2007 Oct 17.

PMID:
17941873
18.

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.

PMID:
18435673
20.

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713.

PMID:
17485570

Supplemental Content

Support Center